Skip to main content
OpenTrials
Completed

NCT Number: NCT00968019

Multicenter Postmarket Surveillance Registry Evaluating Performance and Long Term Safety of the Presillion Stent

The purpose of this study is: To evaluate the safety and performance of the Presillion stent in routine clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Garcia Da Orta, Almada, Portugal

Loading trial locations.

About this study

Primary endpoint: Composite of Major Adverse Cardiac Events (MACE), which includes cardiac death, myocardial infarction (Q-wave and non Q-wave) and clinically driven target lesion revascularization (TLR) at 12 months follow-up.

Data will be collected on 400 patients (from 14 hospitals in Spain and Portugal) treated with the Presillion stent in up to 2 de novo native coronary artery lesions

Study design: multicenter, prospective, observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All subjects treated with Presillion stent up to two de novo coronary artery lesions

Exclusion criteria

  • No specified

Treatment and study plan

Presillion stent

Device

Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).

Primary outcomes

  1. Major Cardiac Adverse Events (Including Cardiac Death, Myocardial Infarction (Q-wave and Non Q-wave) and Clinically Driven TLR (Target Lesion Revascularization))

    Time frame: at 12 months follow-up

    Major adverse cardiac and cerebral events are defined as an adjudicated composite of cardiac death, myocardial infarction (Q-wave and non Q-wave), emergent coronary artery bypass surgery and target vessel revascularization (TVR).

    The primary safety measure was the composite of MACE up to 12 months follow up. In order to show the safety of the device, the MACE rate was compared with the performance goal for bare metal stents(experience with bare metal stents in clinical trials suggested that the 12 month MACE rate should be about 25.0%).

Secondary outcomes

  1. Device Success

    Time frame: Peri-procedure up to discharge

    Device success defined as achievement of a final diameter stenosis of <50% (by visual estimate), using the assigned device only

  2. Lesion Success

    Time frame: Peri-procedure up to discharge

    Lesion success defined as the attainment of <50% final diameter stenosis (by visual estimate) using any percutaneous method.

  3. Procedural Success

    Time frame: Peri-procedure up to discharge

    Procedural success defined as achievement of a final diameter stenosis of <50% (by visual estimate) using any percutaneous method, without the occurrence of death, MI (Myocardial Infarction), or repeat revascularization of the target lesion during the hospital stay

  4. Clinically Driven TLR

    Time frame: Up to 30 days

    Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel

  5. Clinically Driven TVR

    Time frame: Up to 30 days

    Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.

  6. Target Vessel Failure

    Time frame: Up to 30 days

    Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.

    Target vessel failure will be reported when:

    • MI occurs in territory not clearly attributed to a vessel other than the target vessel.
    • Cardiac death not clearly due to a non-target vessel endpoint.
    • Target vessel revascularization is performed.
  7. Myocardial Infarction

    Time frame: Up to 30 days

    A positive diagnosis of myocardial infarction is made when one of the following criteria is met:

    • Typical rise and/or fall of biochemical markers of myocardial necrosis together with evidence of ischemia with at least one of the following:
    • ischemic symptoms
    • ECG changes indicative of ischemia (ST segment elevation or depression)
    • Development of pathological Q waves in the ECG
    • Imaging evidence of new an equivocal loss of viable myocardium or new regional wall motion abnormality
    • Pathological findings of an acute myocardial infarction
  8. Major Bleeding

    Time frame: Up to 30 days

  9. Stroke

    Time frame: Up to 30 days

  10. Stent Thrombosis

    Time frame: Up to 30 days

    Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.

  11. Clinically Driven TLR

    Time frame: up to 12 months

    Target Lesion Revascularization (TLR) is defined as any clinically-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel

  12. Clinically Driven TVR

    Time frame: Up to 12 months

    Target vessel revascularization (TVR) is defined as any clinically driven (as defined for TLR) repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel.

  13. Target Vessel Failure

    Time frame: Up to 12 months

    Target vessel failure includes any target vessel revascularization as well as any MI or any cardiac death that cannot be clearly attributed to a non-target vessel.

    Target vessel failure will be reported when:

    • MI occurs in territory not clearly attributed to a vessel other than the target vessel.
    • Cardiac death not clearly due to a non-target vessel endpoint.
    • Target vessel revascularization is performed.
  14. Myocardial Infarction

    Time frame: Up to 12 months

    A positive diagnosis of myocardial infarction is made when one of the following criteria is met:

    • Typical rise and/or fall of biochemical markers of myocardial necrosis together with evidence of ischemia with at least one of the following:
    • ischemic symptoms
    • ECG changes indicative of ischemia (ST segment elevation or depression)
    • Development of pathological Q waves in the ECG
    • Imaging evidence of new an equivocal loss of viable myocardium or new regional wall motion abnormality
    • Pathological findings of an acute myocardial infarction
  15. Major Bleeding

    Time frame: Up to 12 months

  16. Stent Thrombosis

    Time frame: Up to 12 months

    Thrombosis is defined as the formation of blood clot derived from aggregation of red cells or platelets obstructing the lumen of the vessel.

  17. Stroke

    Time frame: Up to 12 months

Sponsors and collaborators

Lead sponsor

Johnson and Johnson, S.A.

Industry

Registry information

Official study title

A Multicenter Postmarket Surveillance Registry Evaluating the Performance and Long Term Safety of the Presillion Stent in de Novo Native Coronary Artery Lesions. Iberian Registry

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
Aug 28, 2009
Registry last updated
Mar 13, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.